Zevra Therapeutics, Inc. (ZVRA)
11.65
-0.22
(-1.85%)
USD |
NASDAQ |
Aug 24, 16:00
11.66
+0.01
(+0.09%)
After-Hours: 20:00
Zevra Therapeutics EPS Diluted (Quarterly) : 0.1368 for June 30, 2026
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.1368 |
| March 31, 2026 | 0.603 |
| December 31, 2025 | 0.1969 |
| September 30, 2025 | -0.0097 |
| June 30, 2025 | 1.364 |
| March 31, 2025 | -0.0573 |
| December 31, 2024 | -0.6659 |
| September 30, 2024 | -0.695 |
| June 30, 2024 | -0.4756 |
| March 31, 2024 | -0.3979 |
| December 31, 2023 | -0.3998 |
| September 30, 2023 | -0.2986 |
| June 30, 2023 | -0.0759 |
| March 31, 2023 | -0.3835 |
| December 31, 2022 | 0.1622 |
| September 30, 2022 | -0.1918 |
| June 30, 2022 | -0.6979 |
| March 31, 2022 | -0.054 |
| December 31, 2021 | -0.0776 |
| September 30, 2021 | -0.05 |
| June 30, 2021 | -0.3666 |
| March 31, 2021 | -2.493 |
| December 31, 2020 | -1.070 |
| September 30, 2020 | -0.6798 |
| Date | Value |
|---|---|
| June 30, 2020 | 0.2176 |
| March 31, 2020 | -1.915 |
| December 31, 2019 | -2.88 |
| September 30, 2019 | 0.9643 |
| June 30, 2019 | -5.218 |
| March 31, 2019 | -7.365 |
| December 31, 2018 | -3.20 |
| September 30, 2018 | -15.04 |
| June 30, 2018 | -14.56 |
| March 31, 2018 | -28.32 |
| December 31, 2017 | -11.52 |
| September 30, 2017 | -10.88 |
| June 30, 2017 | -7.04 |
| March 31, 2017 | -17.76 |
| December 31, 2016 | -10.88 |
| September 30, 2016 | -14.72 |
| June 30, 2016 | -9.28 |
| March 31, 2016 | -3.20 |
| December 31, 2015 | -10.24 |
| September 30, 2015 | -10.88 |
| June 30, 2015 | -39.20 |
| March 31, 2015 | -40.00 |
| December 31, 2014 | -14.07 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Innoviva, Inc. | -1.136 |
| Collegium Pharmaceutical, Inc. | -0.4637 |
| Johnson & Johnson | 2.268 |
| Ligand Pharmaceuticals, Inc. | 2.221 |
| Harrow, Inc. | -0.4624 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | 8.393M |
| Revenue (Quarterly) | 39.66M |
| Total Expenses (Quarterly) | 31.27M |
| Enterprise Value | 471.26M |
| Gross Profit Margin (Quarterly) | 95.36% |
| Profit Margin (Quarterly) | 21.16% |
| Earnings Yield | 7.96% |
| Operating Earnings Yield | 5.65% |
| Normalized Earnings Yield | 9.737 |